News

OCRF Research Finds Gene Therapy May Help Patients with Recurrent Ovarian Cancer

David Pepin, PhD (July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that gene therapy that delivers a protein that suppresses the development of female reproductive... 

Younger Women with Low Grade Ovarian Cancer Face Worse Outcomes

(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes. Researchers at the... 

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer.¬† The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early... 

Comparison of Clear Cell and Serous Ovarian Cancer- Characteristics and Prognosis

(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had a longer time to recurrance,... 

Body Mass Index Impacts Ovarian Cancer Chemotherapy Dosages

(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of survival, according to a study by researchers at the Rutgers... 

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer¬†patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology. The study enrolled 1,528 women with newly diagnosed ovarian cancer,... 

OCRF Welcomes New Scientific Advisory Committee Members

OCRF recently welcomed three new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRF research grants. Dineo Khabele, M.D., of Vanderbilt University Medical Center, Celeste Leigh Pearce, Ph.D., M.P.H., of University... 

OCRF Researchers Find Clues on Mucinous Ovarian Cancer Origins

(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk and growth of a certain kind of ovarian cancer, known as mucinous ovarian carcinoma, or MOC. The international study... 

Investigators Discover How Ovarian Cancer Halts Body’s Natural Defense Against Tumor

(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. The findings are published in the June... 

Ovarian Cancers Sensitive to Chemo Identified by Gene Mutations

(June 17, 2015) Researchers at MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies....